Evidence map›Paper›PMID 42754721›Full record

ArticlePediatric research2026

Safety and long-term effectiveness of teduglutide in children with intestinal failure due to short bowel syndrome: a multicenter, post-marketing cohort study.

Lissette Jimenez, Aliza Ray, David Mercer, Samuel Kocoshis, Sivan Kinberg, Mercedes Martinez, Lindsey Gumer, Russell Merritt, Mark R Corkins, Charles Vanderpool and 12 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04832087 (Pediatric Teduglutide Registry), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04832087 completednot on this map

Pediatric Teduglutide Registry: Clinical Use of Teduglutide in Children With Intestinal Failure, a Multicenter Post-marketing Evaluation

Typeobservational_patient_registrySponsorBoston Children's HospitalRan2021 to 2023Enrolled142ConditionsShort Bowel SyndromeArmsTeduglutide
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Lissette JimenezDivision of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Aliza RayBiostatistics and Research Design Center, Boston Children's Hospital, Boston, MA, USA.
David MercerDepartment of Surgery, Division of Transplantation, University of Nebraska Medical Center, Omaha, NE, USA.
Samuel KocoshisDivision of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Sivan KinbergDivision of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Irving Medical Center, New York, NY, USA.
Mercedes MartinezDivision of Pediatric Gastroenterology, Hepatology and Nutrition, Columbia University Irving Medical Center, New York, NY, USA.
Lindsey GumerDivision of Gastroenterology, Hepatology, and Nutrition, Children's Hospital Colorado, Aurora, CO, USA.
Russell MerrittDivision of Gastroenterology, Hepatology, and Nutrition, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Mark R CorkinsDivision of Gastroenterology, Hepatology, and Nutrition, Le Bonheur Children's Hospital and University of Tennessee Health Science Center, Memphis, TN, USA.
Charles VanderpoolDivision of Gastroenterology, Hepatology, and Nutrition, Riley Hospital for Children at IU Health, Indianapolis, IN, USA.
Valeria CohranDivision of Gastroenterology, Hepatology, and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Danielle WendelDivision of Gastroenterology and Hepatology, Seattle Children's Hospital, Seattle, WA, USA.
John ThompsonDivision of Gastroenterology, Hepatology, and Nutrition, Children's Hospital at Montefiore, Bronx, NY, USA.
Debra SudanDepartment of Surgery, Duke University Medical Center, Durham, NC, USA.
Kristin Whitfield Van BurenDivision of Gastroenterology, Hepatology, and Nutrition, Texas Children's Hospital, Houston, TX, USA.
Stuart KaufmanTransplant Institute, MedStar Georgetown University Hospital, Washington, DC, USA.
Alexandra N CareyDivision of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Sasan SabrdaranTakeda Development Center Americas, Inc, Cambridge, MA, USA.
Paul MitchellBiostatistics and Research Design Center, Boston Children's Hospital, Boston, MA, USA.
Suzanne E DahlbergBiostatistics and Research Design Center, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Edie WellerBiostatistics and Research Design Center, Boston Children's Hospital, Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Christopher P DugganDivision of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA. Christopher.duggan@childrens.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTeduglutide, a glucagon-like peptide-2 (GLP-2) analog, was approved in the US for use in children with intestinal failure dependent on parenteral support (PS, including intravenous fluids and/or parenteral nutrition (PN)) in 2019.

methodsBetween May 2021 and December 2022, we enrolled 140 children with intestinal failure in a multi-center registry across 14 centers to evaluate the long-term (up to 3 years) safety and effectiveness of teduglutide.

resultsAmong 120 participants in whom effectiveness was measured, the mean percent reduction in parenteral calories was 8.3% by 6 months, 16.5% by 12 months, 33.0% by 2 years and 49.5% by 3 years, estimated by linear mixed models. Cumulative incidence estimates for weaning from parenteral support (full enteral autonomy) were 7.5% by 6 months, 15.2% by 1 year, 26.4% by 2 years, and 32.7% by 3 years from baseline. Five patients had inflammatory/foveolar polyps. The modeled proportion of children with low weight-for-age Z score increased from 2.3% at baseline to 12.7% at 3 years (p < 0.01) and mean BMI Z-scores declined over follow-up as well.

conclusionsIn children treated with teduglutide, we found a progressive and sustained reduction in parenteral support up to 3 years and recommend careful attention to the nutritional status of such patients. IMPACT: The GLP-2 analog medication teduglutide was approved by the FDA in 2019 for children receiving parenteral support for intestinal failure. We enrolled 140 such children to evaluate its safety and effectiveness profile in a post-marketing study. Substantial reductions in parenteral calories and volume were noted with a reasonable safety profile. Some reductions in nutritional status (weight and BMI but not height) were also noted. Careful monitoring of nutritional status while on this new medication is warranted. CLINICAL TRIAL REGISTRY SITE: NCT04832087.

Identifiers

PMID42754721

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.